
The post hoc analysis of the ALLEGRO-LT study assessed long-term response patterns to ritlecitinib in alopecia areata patients. Among 191 participants, 45% achieved a sustained response (SALT ≤20), with 46% reaching complete response. Female sex, shorter disease duration, and less extensive hair loss correlated with better outcomes. Findings suggest extended treatment duration may be necessary for optimal efficacy.
Like
Save
Share